Advanced Enzyme (ADVENZYMES)

FairStock Score: 8/100 — RISKY

Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Negligible leverage with debt-to-equity of 0.02, giving strong balance sheet stability
• High promoter holding of 43.04%, aligning management with minority shareholders
• Solid ROE of 20.02%, indicating efficient use of equity capital
• Modest dividend yield of 1.73% provides some income while waiting

Concerns

• Sales growth of just 1.68% and profit decline of 8.89% show a stagnant or contracting business
• P/E of 23.33 and PEG of 13.89 suggest the valuation is expensive for near-zero growth
• Piotroski F-Score of 4/9 signals weak financial fundamentals and possible deterioration
• Price-to-book of 5.61 leaves little margin of safety for a Graham-style buyer

AI Analysis

When I look at Advanced Enzyme, I see a business with some admirable qualities but also a price that asks for more than the numbers support. It operates in a niche biotechnology space—enzymes are essential, and switching costs can create a decent moat. The balance sheet is fortress-like, with debt-to-equity of just 0.02, and the company generates a robust ROE of 20.02%. Promoters hold 43.04%, so their interests are aligned with mine as a minority shareholder. But then I turn to growth, and my enthusiasm cools. Sales growth is barely 1.68%, and profits have actually fallen 8.89% in the latest year. That is not the hallmark of a growing enterprise; it is a mature, perhaps stagnant business asking for 23.33 times earnings. The PEG ratio of 13.89 screams that you are paying a premium for almost no growth. The Piotroski F-Score of 4/9 also raises red flags—fundamentals are not improving in a way that would make a value investor comfortable. The book value is ₹53.29, so paying ₹298.85 means a price-to-book of 5.61. That leaves very little margin of safety. Yes, the dividend yield of 1.73% gives some comfort, and the latest quarter showed a profit of ₹43 Cr on sales of ₹172 Cr, so the business is not broken. But in my view, you are paying a rich price for a slow, slightly shrinking operation. I would need a much lower entry price or clear evidence of renewed growth before I put my capital here. For now, this is a slow grower with limited upside unless operations genuinely pick up.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer